- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04027452
Electroconvulsive Therapy for Traumatic Memories
Electroconvulsive Therapy for Traumatic Memories: A Randomized Controlled Clinical Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Traumatic events contribute to the genesis of disorders such as post-traumatic stress disorder (PTSD) and depression, and memories of the event can cause ongoing distress. Short-term episodic memories are encoded by the hippocampus and gradually become consolidated through reciprocal connections with the cortex, resulting in long-term memories being stored in a distributed network throughout the cerebral cortex. There are no effective treatments currently for specifically targeting traumatic memories and reducing the distress they cause.
ECT is the most effective treatment for improving mood in patients with depression and there is new evidence emerging that suggests ECT can also improve PTSD symptoms independently of co-morbid depression. In addition, the main side-effect of ECT is memory loss, specifically for autobiographical details surrounding the course of ECT, but not typically affecting long-term episodic memory, nor procedural memories. Memories stored in the hippocampus are vulnerable to disruption by ECT because they rely on synaptic changes that are mediated by relatively unstable modifications in AMPA receptor and metabotropic glutamate receptor density. The investigators propose to exploit this feature of ECT, which normally is considered an undesirable side-effect of treatment, in an attempt to selectively reduce traumatic memories and the distress associated with them.
The investigators propose to recruit patients referred for ECT for treatment-resistant depression, who also have traumatic memories that are causing distress. These patients will be asked to write two narratives, one of the traumatic memory, and the other of a trivial, non-traumatic remote event. Patients will then be asked to listen to an audio recording of either the traumatic memory or the neutral memory (control group) immediately before their ECT sessions. The severity of the traumatic memory related symptoms will be assessed before and after the course of ECT using the Modified PTSD Symptom Scale (MPSS-SR) and the Clinician Administered PTSD Scale for DSM-5 (CAPS-5). Data will be analyzed by comparing the change in overall MPSS-SR scores and CAPS-5 scores pre- and post-ECT between the experimental and control groups. Physiological data will also be collected at each ECT session during the time the participant is listening to the audio recordings. Heart rate and skin conductance will be measured prior to and during listening of the traumatic or non-traumatic memory, in order to determine if there is a change associated with a stress response, and whether this response normalizes in association with reduction of PTSD symptoms with treatment.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5T 1L8
- Centre for Addiction and Mental Health
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient referred and accepted for ECT treatment at CAMH
- Presence of traumatic memories
- Able to write about their traumatic experience(s)
- Capable of informed consent to participate in this study
- Age 18 or greater
- MPSS-SR re-experiencing score (items 1-4, 17) ≥ 20
Exclusion Criteria:
- History of neurological or developmental disorder, including seizures
- ECT treatment already started
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Traumatic memory reactivation
Audio recording of traumatic memory that triggers symptoms of PTSD, anxiety, depression, played before each ECT treatment.
|
125 word long "exposure scripts" of their traumatic memory recorded in a neutral tone.
All recordings will be approximately 30 seconds in length and the traumatic script will include five of the physical symptoms related to the memory as described by the patient.
The script recording is preceded with short instructions for the subject to concentrate on the script and to imagine the described experience for additional 30 seconds right after the script until a short beep sounds.
When the participant enters the treatment room, they will be handed an MP3 player with the audio recording.
The patient will have several minutes to listen to the recording while the standard pre-ECT procedures are conducted.
The participant will listen to the recording prior to each of their ECT treatments for the duration of their acute treatment course.
|
Placebo Comparator: Neutral memory reactivation
Audio recording of neutral (non-traumatic) memory played before each ECT treatment.
|
125 word long "exposure scripts" of a neutral (non-traumatic) memory recorded in a neutral tone.
All recordings will be approximately 30 seconds in length and the traumatic script will include five of the physical symptoms related to the memory as described by the patient.
The script recording is preceded with short instructions for the subject to concentrate on the script and to imagine the described experience for additional 30 seconds right after the script until a short beep sounds.
When the participant enters the treatment room, they will be handed an MP3 player with the audio recording.
The patient will have several minutes to listen to the recording while the standard pre-ECT procedures are conducted.
The participant will listen to the recording prior to each of their ECT treatments for the duration of their acute treatment course.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Modified PTSD Symptom Scale (MPSS-SR) score
Time Frame: Baseline, after ECT treatment course (an average of 4 weeks), and at 3 month follow up
|
17-item self-report measure that assesses the DSM-III-R symptoms of PTSD.
Score range from 0-119, higher score indicates greater PTSD symptom severity.
|
Baseline, after ECT treatment course (an average of 4 weeks), and at 3 month follow up
|
Change in Clinician Administered PTSD Scale for DSM-5 (CAPS-5) score
Time Frame: Baseline, after ECT treatment course (an average of 4 weeks), and at 3 month follow up
|
30-item semi structured interview that is used to index of PTSD severity and assess PTSD symptoms over the past week.
In addition to assessing the 20 DSM-5 PTSD symptoms, questions target the onset and duration of symptoms, subjective distress, and impact of symptoms on social and occupational functioning, improvement in symptoms since a previous CAPS administration, overall response validity, and features for the dissociative subtype (depersonalization and derealization).
Administration requires identification of an index traumatic event to serve as the basis for symptom inquiry.
Symptom severity scores range from 0 to 80, higher score indicates greater PTSD symptom severity.
|
Baseline, after ECT treatment course (an average of 4 weeks), and at 3 month follow up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in heart rate
Time Frame: Change of heart rate from 0-30 seconds of the audio recording to heart rate from 90-120 seconds of the audio recording.
|
Heart rate change before and after listening to script of traumatic or neutral memory
|
Change of heart rate from 0-30 seconds of the audio recording to heart rate from 90-120 seconds of the audio recording.
|
Skin conductance
Time Frame: Change of skin conductance from 0-30 seconds of the audio recording to skin conductance from 90-120 seconds of the audio recording.
|
Skin conductance change before and after listening to script of traumatic or neutral memory
|
Change of skin conductance from 0-30 seconds of the audio recording to skin conductance from 90-120 seconds of the audio recording.
|
Change in The Quick Inventory of Depressive Symptomatology (Self-Report)
Time Frame: Baseline, after ECT treatment course (an average of 4 weeks), and at 3 month follow up
|
Self report scale of depressive symptoms.
Scores range from 0-27, higher score indicates greater depression severity.
|
Baseline, after ECT treatment course (an average of 4 weeks), and at 3 month follow up
|
Collaborators and Investigators
Investigators
- Principal Investigator: Albert HC Wong, MD, FRCPC, PhD, Centre for Addiction and Mental Health
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 063/2015
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Lawson Health Research InstituteTerminated
Clinical Trials on Traumatic memory reactivation
-
Northwestern UniversityRecruitingSleep | ConsolidationUnited States
-
Northwestern UniversityCompletedSleep | ConsolidationUnited States
-
Northwestern UniversityCompletedSleep | ConsolidationUnited States
-
Northwestern UniversityRecruitingStrokeUnited States
-
Shenzhen Kangning HospitalScience and Technology Innovation Commission of Shenzhen MunicipalityNot yet recruiting
-
University of PennsylvaniaNational Institute of Mental Health (NIMH)RecruitingMemory ConsolidationUnited States
-
University Hospital, GenevaCompletedSleep | Social Anxiety DisorderSwitzerland
-
University Hospital, GenevaRecruitingPTSD | Nightmares, REM-Sleep TypeSwitzerland
-
University Hospital, GenevaCompletedNightmares, REM-Sleep TypeSwitzerland
-
Douglas Mental Health University InstituteCompleted